Summary.-The development of serum factors by Wistar rats during the growth of a syngeneic squamous cell carcinoma has been investigated to clarify the nature of the local lymphocyte anergy reported previously in this system. Sera from tumour bearing animals were tested for cytotoxicity against tumour cells by in vitro microassay, and their ability to inhibit cell mediated cytotoxicity was also studied. Serum cytotoxicity was first detected after 2 weeks of tumour growth, reaching a peak at 4 weeks and then declining. Inhibitory activity was found only in the sera of animals with advanced tumours. Anti-tumour antibody either in the sera or bound-to tumour cells was not detected by immunofluorescence techniques. No evidence of general immunological debilitation was found, the animals showing normal immune responses to sheep erythrocytes and killed Brucella abortus organisms throughout tumour growth. Serum inhibitory factors may be responsible for the decline in antitumour immunoreactivity and the local lymphocyte anergy observed in tumour bearing hosts.
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LOCAL lymphocyte anergy has been reported previously in a study of the development of cell mediated immunity to a syngeneic squamous cell carcinoma in inbred Wistar rats (Flannery et al., 1973) . Regional node lymphocytes, cytotoxic to tumour cells early in tumour growth, lose this ability as the tumour progresses and become totally unresponsive whereas spleen and blood lymphocytes retain a significant degree of cytotoxicity. It has been shown that factors present in the sera of tumour bearing hosts interfere with lymphocyte-mediated tumour-cell destruction (reviewed by . These factors include excess tumour antigen (Alexander, 1970) , anti-tumour antibody (Hellstr6m and Hellstr6m, 1970) and antigen-antibody complexes (Baldwin, Price and Robins, 1972; Sjogren et al., 1972) . We have studied the evolution of serum cytotoxicity and blockade throughout the period of tumour growth in rats to investigate any relationship between these factors and regional anergy.
MATERIAL AND METHODS
Animals and tumour.-The growth of a transplantable squamous cell carcinoma in Wistar rats and the use of tumour cell suspensions for inoculation and cytotoxicity assays have been described previously (Flanneryetal., 1973) .
Tumour growth in vivo.-The pattern of tumour growth in vivo was studied in 2 groups of animals: (i) Rats inoculated subcutaneously in the medial aspect of the right thigh with 103 viable tumour cells, previously shown to produce tumours in all animals and death in 8-10 weeks. Groups of 4 animals were killed 2, 4, 6 and 8 weeks after inoculation. (ii) Rats inoculated similarly with 104 viable tumour cells, previously shown to kill all animals in 6-8 weeks. Groups of 5 animals were killed weekly after tumour inoculation and the volumes of the primary tumours were determined (Flannery et al., 1973) .
Immunological studies in vitro
Serum cytotoxicity. Sera were tested for in vitro complement-dependent cytotoxicity to tumour cells by a modification of the method of Bloom (1970 (Flannery et al., 1973 (Nairn, 1969) using an apparatus designed to facilitate simultaneous handling of up to 40 sera (Nairn, Cusdin and McNaughtan, 1971) . A fluorescein labelled rabbit anti-rat globulin with a fluorescein to protein molar ratio of 4 3 1 was used at a globulin concentration of 0 7 g/100 ml. This conjugate had been absorbed with human liver powder, bovine liver homogenate and well washed rat erythrocytes and had activity against IgG and IgM. By itself it gave no fluourescent staining of rat tumour cells or thymocytes.
Frozen sections.-Fresh blocks of tumour, up to 5 mm square x 2 mm thick, wNere excised from each rat killed 2, 4, 6 and 8 wNeeks after inoculation wNith 103 tumour cells. Blocks were snap frozen in a liquid nitrogenisopentane mixture and stored at -70°C.
Sections, 6 [km, were cut and stained by direct immunofluorescence using standard controls (Nairn, 1969) , and the fluorescein labelled rabbit anti-rat globulin described above.
Impression filmsn-Frozen tumour blocks were thawed to room temperature and impression films made by pressing the tissue against gelatinized glass slides (Nairn, 1969 Response to Brucella was also determined by agglutination assay in microtitre trays with a 1 in 250 dilution of the haemotoxylin stained Brucella preparation.
RESULTS

Tumour growth
The pattern of tumour growth in both groups of animals was similar.
Tumours became palpable 2-4 weeks after inoculation and then increased rapidly in volume, reaching a mean size of 17-1 ± 80 cm3 in the rats inoculated with 103 cells, and 11b6 + 4-6 cm3 after 104 cells. Metastases were observed microscopically in the lungs of some animals when tumours became palpable, and of all animals by Week 6.
Serum cytotoxicity
The time course of serum cytotoxicity is shown in Fig. 1 8-10 (9) 11-13 (12) 4 8-9 (8) 11-14 (13) 6 6-8 (8) 10-13 (12) 8 1*-9 (6) 11-14 (13) Normal controls 8-10 (9) 11-14 (13) (10 animals) * Titre of 1 rat only below normal range.
sheep red cells at Week 8, due to a low titre in one rat, was not statistically significant.
DISCUSSION
We have studied the development, in tumour bearing hosts, of serum factors capable of tumour cell destruction and factors able to inhibit lymphocyte cytotoxicity. Serum mediated cytotoxicity became apparent early in tumour growth and then declined. The size of the initial tumour inoculum did not alter this pattern. A similar time course has been reported for the development of lymphocytotoxicity in these animals (Flannery et al., 1973) .
The complement dependence of the serum cytotoxicity and the work of others (Takasugi and Hildemann, 1969; Ankerst, 1971) implicate antibodies in this reaction. The serum concentration of such antibodies was in any case low, as no activity against tumour cell membrane antigens was detected by immunofluorescence. In view of the similar decline in lymphocyte cytotoxicity, the observed reduction in serum reactivity may have been due to a lymphocyte impairment, either as a direct B cell deficiency or as a defect in T cell collaboration. A general immunological debilitation, however, was not demonstrated: normal antibody responses were maintained in tumour bearing animals to Brucella abortuas, a measure primarily of B cell function (Crewther and Warner, 1972; Hard, G. C. personal communication) and to sheep erythrocytes, a function requiring T and B cell co-operation (Claman and Chaperon, 1969 ). An alternative hypothetical explanation, which has not yet been studied, would be a shift in the production of IgM antibody to less lytic IgG antibody during maturation of the immune response (Takasugi and Hildemann, 1969; Ankerst, 1971) .
Inhibition of lymphocyte cytotoxicity by sera of tumour bearing animals was seen in later stages of tumour growth. We have not yet investigated the nature of the serum blocking factors in our system, but their occurrence may be another explanation for the decline in antitumour immunoreactivity. The late detection of blocking may have been due to the relatively low sensitivity of the technique used, as others (Sjogren and Borum, 1971 ) have reported the appearance of blocking factors throughout tumour growth. Alternatively, the appearance of blocking factors and the disappearance of cytotoxic antibody may be associated with the concurrent growth of metastases. The possibility of " unblocking factors " (Hellstrom and Hellstrom, 1970; Bansal and Sjogren, 1971 ) earlier in tumour growth has not been investigated in our system.
In vivo, blocking factors might act on effector lymphocytes or on tumour cells. Circulating lymphocytes will be more accessible to humoral factors and specific depression of lymphocytes has been described (Field and Caspary, 1972) . Currie and Basham (1972) have demonstrated that washing of lymphocytes from cancer patients increased their cytotoxic activity; subsequent incubation of the prewashed lymphocytes with autologous serum abolished this reactivity. The anergy of local lymphocytes in our system (Flannery et al., 1973) (Bansal, Hargreaves and Sj6gren, 1972; Ran and Witz, 1972; Sjogren et al., 1972) . Others Cohen, Millar and Ketcham, 1972) have demonstrated blocking by incubation of tumour cells with serum but failed to show inhibition by similar incubation of lymphocytes. Such tumour bound factors cannot account for the lymphocyte anergy we observed and their in vivo significance is unclear. Evidence that inhibitory factors may be antigen-antibody complexes (Sjogren et al., , 1972 Baldwin et al., 1972) suggests that they might be able to act on lymphocytes whilst bound to tumour cells (Sjogren et al., 1972) . In our studies, binding of antibodies to lymphocytes or tumour cells was not detected by immunofluorescence, presumably due, if present, to their low in vivo levels.
We have shown a local lymphocyte anergy and the presence in serum of factors capable of inhibiting lymphocytotoxicity. If blocking factors are responsible for in vivo loss of lymphocyte reactivity, there must be some local component to account for the early development of anergy in the regional nodes. This local factor seems most likely to be excess tumour antigen which may then pass into the serum, perhaps complexed with antibody, as the inhibitor we have detected. The isolation and characterization of this factor(s) are proceeding.
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